Clifton Star Resourc (CFMSF) 0.1175 $CFMSF Clifton Star

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Clifton Star Resourc (CFMSF) 0.1175 $CFMSF

Clifton Star Announces Withdrawal and Consequent Cancellation of Requisitioned Meeting
Marketwired - Wed May 27, 10:33AM CDT
Clifton Star Resources Inc. ("Clifton Star" or the "Company" (TSX VENTURE: CFO) (FRANKFURT: C3T) today is pleased to announce that it has received written notification from shareholders Harry Miller and Nick Segounis, who had earlier requisitioned a meeting of Clifton Star's shareholders, indicating that their requisition has been withdrawn. As a result of the withdrawal of the requisition, the meeting has been cancelled.
CFO.VN: 0.145 (-0.015)

Concerned Shareholder Withdraws Requisition for a Special Meeting of Shareholders of Clifton Star Resources Inc.
Marketwired - Tue May 26, 4:19PM CDT
Harry Miller, the former President of Clifton Star Resources Inc. (the "Company", announced today that his Requisition for a Special Meeting of Shareholders to replace the Board of Directors has been withdrawn. This decision follows the completion of the highly dilutive private placements that the Company announced on March 2, 2015.

Clifton Star's Update and Q3 Quarterly Results
Marketwired - Tue May 26, 10:34AM CDT
Clifton Star Resources Inc. ("Clifton Star" or the "Corporation" (TSX VENTURE: CFO)(FRANKFURT: C3T) is pleased to announce that it has mailed, on May 21st, 2015, the Circular and Proxy forms for the June 16, 2015, Special Meeting of Shareholders. The record date was May 12, 2015. Shareholders are asked to contact Kingsdale Shareholder Services at 1-855-683-3113, with any questions and for assistance recording their votes.
CFO.VN: 0.145 (-0.015)

Clifton Star Resources Announces Closing of Private Placements
Marketwired - Wed Mar 11, 3:32PM CDT
Clifton Star Resources Inc. ("Clifton Star" or the "Corporation" (TSX VENTURE: CFO)(FRANKFURT: C3T) is pleased to announce that, further to its press release dated March 2, 2015, the Corporation received final TSX-V Exchange approval and effective March 2, 2015 completed two separate non-brokered private placements issuing a total of 9,545,572 common shares to two placees at a price of $0.60 per common share for total proceeds of C$5,727,343.20.
CFO.VN: 0.145 (-0.015)

IIROC Trade Resumption - Clifton Star Resources Inc.
Newsfile Corp - Mon Mar 02, 8:21AM CST
Trading resumes in:

Clifton Star Resources Announces Private Placements and Settlement of its Osisko Litigation Raising $11 million
Marketwired - Mon Mar 02, 8:08AM CST
Clifton Star Resources Inc. ("Clifton Star" or the "Corporation" (TSX VENTURE: CFO)(FRANKFURT: C3T) is pleased to announce the successful settlement of its claim under the December 2009 commitment letter with Osisko Mining Corporation ("Osisko" (now Canadian Malartic Corporation ("Canadian Malartic") and the subsequent litigation instituted against Osisko by Clifton Star last June in which Clifton Star alleged that Osisko had failed to provide it with a loan pursuant to the commitment letter. Discussions to resolve the matter accelerated following the joint acquisition of Osisko by Yamana Gold Inc. ("Yamana" and Agnico Eagle Mines Limited ("Agnico Eagle" last summer, and Clifton Star wishes to thank them for their efforts to resolve the matter in a timely manner.
CFO.VN: 0.145 (-0.015)

IIROC Trade Halt - Clifton Star Resources Inc.
Newsfile Corp - Mon Mar 02, 7:23AM CST
The following issues have been halted by IIROC:

Update for Clifton Star Resources Inc. Shareholders
Marketwired - Tue Jan 13, 9:56AM CST
That is the question being asked by the shareholders of Clifton Star Resources Inc. ("Clifton" or the "Company" after a news release dated January 9th issued by the Company's CEO, Michel Bouchard.

Clifton Star Sets Date for Requisitioned Meeting
Marketwired - Fri Jan 09, 3:31PM CST
Clifton Star Resources Inc. ("Clifton Star" or "Company" (TSX VENTURE: CFO)(FRANKFURT: C3T) today announced it has called a special meeting of shareholders to be held on June 16, 2015. Clifton Star will provide notice of the record date for receiving notice of and voting at the meeting in due course. More information about the meeting will be provided in a management information circular to be mailed to shareholders and posted to SEDAR in advance of the meeting.
CFO.VN: 0.145 (-0.015)

Clifton Star Resources Reports on Voting Results From 2014 Annual Meeting
Marketwired - Wed Dec 17, 4:03PM CST
Clifton Star Resources Inc. ("Clifton Star" or the "Company" (TSX VENTURE: CFO)(FRANKFURT: C3T) today announced the re-election of management's slate of nominees (Michel Bouchard, Ross Glanville, Peter Gundy, and Philip Nolan) at the Company's annual meeting of shareholders.
CFO.VN: 0.145 (-0.015)

Message to Shareholders of Clifton Star Resources Inc.: A Fair Contest
Marketwired - Mon Dec 15, 8:27AM CST
The dissent slate has formally requested a postponement of the AGM to allow for the shareholders to have a clear choice in the decision as to which group would best serve the interests of the shareholders. Arrogantly, they refused. Not only have the directors declined to allow you that choice, but they hired a Toronto area proxy solicitation company to badger you at a cost of upwards of $200,000 including a success fee to canvass shareholders for the AGM where the outcome is already known. With a call for an extraordinary meeting, management will be spending a like amount to protect its interests. Is this the best use of your money?

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading